AbbVie PE Ratio 2012-2026 | ABBV

Current and historical p/e ratio for AbbVie (ABBV) from 2012 to 2026. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. AbbVie PE ratio as of June 05, 2026 is 20.79.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
AbbVie PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2026-06-05 227.23 111.94
2026-03-31 215.70 $2.03 106.26
2025-12-31 224.80 $2.36 95.25
2025-09-30 226.17 $1.31 172.65
2025-06-30 179.76 $2.09 86.01
2025-03-31 201.05 $2.34 85.92
2024-12-31 168.93 $2.39 70.68
2024-09-30 186.23 $2.87 64.89
2024-06-30 160.28 $2.99 53.60
2024-03-31 168.59 $3.36 50.18
2023-12-31 142.11 $2.72 52.25
2023-09-30 135.34 $3.67 36.88
2023-06-30 120.99 $4.88 24.79
2023-03-31 141.81 $4.25 33.37
2022-12-31 142.45 $6.63 21.49
2022-09-30 117.11 $7.49 15.63
2022-06-30 132.40 $7.06 18.75
2022-03-31 138.96 $6.97 19.94
2021-12-31 114.87 $6.45 17.81
2021-09-30 90.42 $4.06 22.27
2021-06-30 93.38 $3.57 26.16
2021-03-31 88.63 $2.69 32.95
2020-12-31 86.74 $2.72 31.89
2020-09-30 69.96 $4.73 14.79
2020-06-30 77.47 $4.70 16.48
2020-03-31 59.23 $5.65 10.48
2019-12-31 67.92 $5.28 12.86
2019-09-30 57.25 $2.25 25.44
2019-06-30 54.15 $2.80 19.34
2019-03-31 59.23 $3.57 16.59
2018-12-31 66.93 $3.66 18.29
2018-09-30 67.94 $4.85 14.01
2018-06-30 65.88 $4.05 16.27
2018-03-31 66.62 $3.98 16.74
2017-12-31 67.58 $3.30 20.48
2017-09-30 61.67 $4.11 15.00
2017-06-30 49.87 $4.07 12.25
2017-03-31 44.37 $3.86 11.50
2016-12-31 42.22 $3.63 11.63
2016-09-30 42.13 $3.71 11.36
2016-06-30 41.00 $3.48 11.78
2016-03-31 37.47 $3.33 11.25
2015-12-31 38.45 $3.13 12.29
2015-09-30 34.99 $1.70 20.58
2015-06-30 42.90 $1.27 33.78
2015-03-31 37.07 $1.12 33.09
2014-12-31 41.13 $1.10 37.39
2014-09-30 36.03 $2.30 15.67
2014-06-30 34.94 $2.59 13.49
2014-03-31 31.54 $2.57 12.27
2013-12-31 32.15 $2.56 12.56
2013-09-30 26.99 $2.84 9.50
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $367.673B $61.160B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $887.629B 38.81
Johnson & Johnson (JNJ) United States $574.358B 22.08
Roche Holding AG (RHHBY) Switzerland $318.782B 0.00
Merck (MRK) United States $299.893B 13.54
Novartis AG (NVS) Switzerland $293.951B 17.16
Novo Nordisk (NVO) Denmark $167.527B 9.60
Pfizer (PFE) United States $153.074B 8.33
Sanofi (SNY) France $114.048B 10.56
Bayer (BAYRY) Germany $46.178B 8.70
Innoviva (INVA) United States $1.760B 5.88